DE69929323D1 - Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen - Google Patents

Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen

Info

Publication number
DE69929323D1
DE69929323D1 DE69929323T DE69929323T DE69929323D1 DE 69929323 D1 DE69929323 D1 DE 69929323D1 DE 69929323 T DE69929323 T DE 69929323T DE 69929323 T DE69929323 T DE 69929323T DE 69929323 D1 DE69929323 D1 DE 69929323D1
Authority
DE
Germany
Prior art keywords
heparin
binding affinity
growth factor
affinity growth
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69929323T
Other languages
English (en)
Other versions
DE69929323T2 (de
Inventor
E Sakiyama-Elbert
A Hubbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eidgenoessische Technische Hochschule Zurich ETHZ
Universitaet Zuerich
Original Assignee
Eidgenoessische Technische Hochschule Zurich ETHZ
Universitaet Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eidgenoessische Technische Hochschule Zurich ETHZ, Universitaet Zuerich filed Critical Eidgenoessische Technische Hochschule Zurich ETHZ
Application granted granted Critical
Publication of DE69929323D1 publication Critical patent/DE69929323D1/de
Publication of DE69929323T2 publication Critical patent/DE69929323T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
DE69929323T 1999-04-22 1999-04-22 Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen Expired - Lifetime DE69929323T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1999/000800 WO2000064481A1 (en) 1999-04-22 1999-04-22 Controlled release of growth factors from heparin containing matrices

Publications (2)

Publication Number Publication Date
DE69929323D1 true DE69929323D1 (de) 2006-03-30
DE69929323T2 DE69929323T2 (de) 2006-09-07

Family

ID=11004855

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69929323T Expired - Lifetime DE69929323T2 (de) 1999-04-22 1999-04-22 Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen

Country Status (9)

Country Link
EP (1) EP1178834B1 (de)
JP (1) JP2002542301A (de)
AT (1) ATE314863T1 (de)
AU (1) AU3438199A (de)
CA (1) CA2369579A1 (de)
DE (1) DE69929323T2 (de)
ES (1) ES2255257T3 (de)
MX (1) MXPA01010567A (de)
WO (1) WO2000064481A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106001B2 (en) * 1996-08-27 2012-01-31 University Of South Florida Diagnostic markers of human female infertility
US7601685B2 (en) 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6894022B1 (en) 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
ES2330187T3 (es) * 2000-05-01 2009-12-07 Eidgenossisch Technische Hochschule Zurich Matrices proteicas modificadas por factor de crecimiento para ingenieria de tejidos.
ES2321068T3 (es) 2001-04-25 2009-06-02 Eidgenossische Technische Hochschule Zurich Matrices de suministro de farmacos para mejorar la curacion de heridas.
AU2002365162A1 (en) 2001-11-14 2003-07-09 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
US7371719B2 (en) 2002-02-15 2008-05-13 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
US7482427B2 (en) 2002-08-20 2009-01-27 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
US7534761B1 (en) 2002-08-21 2009-05-19 North Western University Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
WO2004046167A2 (en) 2002-11-14 2004-06-03 Northwestern University Synthesis and self-assembly of abc triblock bola peptide
WO2004072104A2 (en) 2003-02-11 2004-08-26 Northwestern University Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
US7452679B2 (en) 2003-12-05 2008-11-18 Northwestern University Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof
JP4851939B2 (ja) 2003-12-05 2012-01-11 ノースウエスタン ユニバーシティ 自己−集合性ペプチド両親媒性物質および増殖因子送達のための関連する方法
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
KR20070108555A (ko) 2005-03-04 2007-11-12 노오쓰웨스턴 유니버시티 혈관신생 헤파린 결합 펩티드 양친매성 화합물
US7517856B2 (en) * 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
WO2007150053A2 (en) 2006-06-22 2007-12-27 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
JP2010516703A (ja) * 2007-01-18 2010-05-20 バクスター・インターナショナル・インコーポレイテッド ＴＧＦ−βの制御放出のためのフィブリンゲルおよびその使用
ES2381639T3 (es) 2007-04-13 2012-05-30 Kuros Biosurgery Ag Sellante polimérico para tejidos
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
WO2009083544A2 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
KR100971271B1 (ko) * 2008-04-28 2010-07-20 한양대학교 산학협력단 헤파린이 결합된 피브린젤, 그 제조방법 및 키트
JP2012523463A (ja) 2009-04-13 2012-10-04 ノースウエスタン ユニバーシティ 軟骨再生のための新規なペプチドベースの足場およびその使用方法
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
US9731046B2 (en) 2012-02-21 2017-08-15 Ben Gurion University Of The Negev Research And Development Authority Hydrogel system comprising spatially separated bioactive polypeptides
EP2946011B1 (de) 2013-01-17 2019-04-17 The Regents of The University of California Wachstumsfaktorsequestrierung mit hydrogelen
EP3080246A4 (de) * 2013-12-11 2017-05-24 The Regents of The University of California Zusammensetzungen und verfahren zur herstellung und verabreichung von braunen adipozyten
JP7033066B2 (ja) 2016-01-07 2022-03-09 ビー．ジー．ネゲブ テクノロジーズ アンド アプリケーションズ リミテッド， アット ベン‐グリオン ユニバーシティー 免疫寛容応答を生成する組成物及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1294546C (en) * 1986-04-23 1992-01-21 John S. Sundsmo Wound healing composition containing collagen
EP0349048A3 (de) * 1988-06-27 1990-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Osteogenische Wachstumsfaktoren, die aus Knochenmark gewonnen werden
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
CA2097063C (en) * 1990-11-27 2006-08-08 Howard P. Greisler Tissue sealant and growth factor containing compositions that promote accelerated wound healing
GB9101183D0 (en) * 1991-01-18 1991-02-27 Univ London Depot formulations
US5693341A (en) * 1995-03-16 1997-12-02 Collagen Corporation Affinity bound collagen matrices for the delivery of biologically active agents
CA2217134A1 (en) * 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
GB9722604D0 (en) * 1997-10-28 1997-12-24 Cancer Res Campaign Tech Heparin-binding growth factor derivatives
AUPP298498A0 (en) * 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
EP1107791B8 (de) * 1998-09-04 2007-11-07 Scios Inc. Hydrogelzusammensetzungen mit kontrollierter freigabe für die verabreichung von wachstumsfaktoren
DE19841698A1 (de) * 1998-09-11 2000-03-16 Curative Technologies Gmbh Wachstumsfaktor-enthaltende Zusammensetzung zur Heilung von Gewebeschäden

Also Published As

Publication number Publication date
EP1178834A1 (de) 2002-02-13
EP1178834B1 (de) 2006-01-04
MXPA01010567A (es) 2005-04-29
DE69929323T2 (de) 2006-09-07
ATE314863T1 (de) 2006-02-15
CA2369579A1 (en) 2000-11-02
ES2255257T3 (es) 2006-06-16
JP2002542301A (ja) 2002-12-10
AU3438199A (en) 2000-11-10
WO2000064481A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
DE69929323D1 (de) Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen
CA2371462A1 (en) Modified protein matrices
Tsurkan et al. Modular StarPEG‐Heparin Gels with Bifunctional Peptide Linkers
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
DE69230823D1 (de) Polymere oberflächenbeschichtungszusammensetzungen
DE69739169D1 (de) Auf temperatur ansprechendes gel zur verzögerten freisetzung von proteinarzneistoffen
DK0814827T3 (da) Karendotel-vækstfaktor-B
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
ATE413415T1 (de) Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate
JP2002542301A5 (de)
DE69708304D1 (de) Vernetzte copolymere auf der basis von polycarbonsäurepolymeren
SE8804164D0 (sv) Farmaceutisk beredning
WO2003084481A3 (en) Biological affinity based delivery systems
NZ514488A (en) Vascular endothelial cell growth factor variants and uses thereof
DE69231065T2 (de) Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
DE69712124T2 (de) Hormones de croissance humaines mutantes et leur utilisation
Yamada et al. Biological activity of laminin peptide‐conjugated alginate and chitosan matrices
Clauder et al. Peptide‐mediated surface coatings for the release of wound‐healing cytokines
Douglas et al. Influence of collagen‐fibril‐based coatings containing decorin and biglycan on osteoblast behavior
WO1993015203A3 (en) Polypeptides with fibronectin binding sites as modulators for matrix assembly
IT1264447B1 (it) Espressione di oncogeni derivati da ntrki in cellule di feocromocitoma pc12 ed utilizzo di questo sistema come screening di sostanze di
ATE293641T1 (de) Vernetzte copolymere auf der basis von nicht vernetzten polycarbonsäurepolymeren
NO990471L (no) Farmasoeytisk sammensetning av pinnsvinproteiner og anvendelse derav
Behrens et al. Development of a system of heparin multilayers on titanium surfaces for dual growth factor release

Legal Events

Date Code Title Description
8364 No opposition during term of opposition